Who are Human Papillomavirus Tumor Antigen Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, MMR（0d），HPV（1m），HPV（7m）, COMIRNATY - BioNTech Manufacturing GmbH, bOPV, MMR vaccination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/human-papillomavirus-tumor-antigen-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Human Papillomavirus Tumor Antigen Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human Papillomavirus Tumor Antigen Vaccine (Human Papillomavirus Tumor Antigen Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Vaccines.

phase 2 Vaccine Vaccines Biologic Live · refreshed every 30 min

Target snapshot

Human Papillomavirus Tumor Antigen Vaccine (Human Papillomavirus Tumor Antigen Vaccine) — Michael K. Gibson. Stimulates an immune response against Human Papillomavirus (HPV) tumor antigens

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Human Papillomavirus Tumor Antigen Vaccine TARGET	Human Papillomavirus Tumor Antigen Vaccine	Michael K. Gibson	phase 2	Vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
MMR（0d），HPV（1m），HPV（7m）	MMR（0d），HPV（1m），HPV（7m）	Zhejiang Provincial Center for Disease Control and Prevention	marketed	vaccine
COMIRNATY - BioNTech Manufacturing GmbH	COMIRNATY - BioNTech Manufacturing GmbH	Jens D Lundgren, MD	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
bOPV	bOPV	Aga Khan University	marketed	Live attenuated vaccine	Poliovirus serotypes 1 and 3
MMR vaccination	MMR vaccination	Klara M. Pósfay Barbe	marketed	Live attenuated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

GlaxoSmithKline · 16 drugs in this class
Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
Pfizer · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Henogen · 3 drugs in this class
Pfizer Inc. · 2 drugs in this class
Sanofi · 2 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
BioNTech · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Human Papillomavirus Tumor Antigen Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/human-papillomavirus-tumor-antigen-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab